Cellular Biology |
From the Shanghai Institute of Cell Biology (Q.J., S.-M.X., W.-B.Z., P.W., G.P.), Chinese Academy of Sciences, and Department of Cardiology (Q.J., Y.-W.Q.), Changhai Hospital, Second Military Medical University, Shanghai, Peoples Republic of China.
Correspondence to Gang Pei, PhD, Shanghai Institute of Cell Biology, Chinese Academy of Sciences, 320 Yue-Yang Rd, Shanghai 200031, Peoples Republic of China. E-mail gangpei{at}sunm.shcnc.ac.cn
| Abstract |
|---|
|
|
|---|
Key Words: atherosclerosis lysophosphatidylcholine mitogen-activated protein kinase monocytes chemotaxis
| Introduction |
|---|
|
|
|---|
Mitogen-activated protein kinases (MAPKs) are serine-threonine
kinases that perform important functions as mediators of cellular
responses to a variety of extracellular stimuli. The following 4 major
subfamilies of structurally related MAPKs have been identified in
mammalian cells12 13 14 : the extracellular signalregulated
kinases (ERK1/ERK2, also termed p42/44 MAPK), the c-Jun N-terminal
kinase/stress-activated protein kinases (JNK/SAPK), big MAPK1
(BMK1), and p38 MAPK (p38), a more recently described member of the
family. The subfamily of p42/44 is characteristically activated
by various growth factors and associated with cell proliferation and
hypertrophy. The subfamily of p38, containing at least 4
members (
, ß,
, and
),13 15 16 17 18 19 is strongly
activated in response to stress stimuli and proinflammatory
cytokines. Some evidence suggests that activation of p38
triggers several growth factordirected endothelial
cell20 and smooth muscle cell21 migrations.
Recent reports have shown that OxLDL and LPC are able to
activate p42/4422 23 24 25 in several cultured cell
lines, and our previous study demonstrated that OxLDL strongly
activated p38 in vascular smooth muscle cells,26
but it is unclear yet whether LPC can stimulate both kinds of MAPKs in
monocytes. The current study, therefore, was undertaken to investigate
the possible MAPK activation by OxLDL/LPC and the potential involvement
of MAPK activation in OxLDL-/LPC-stimulated chemotaxis of monocytic
THP-1 cells.
| Materials and Methods |
|---|
|
|
|---|
Cell Culture
Monocytic THP-1 cells (American Type Culture Collection) were
cultured in RPMI 1640 supplemented with 10%
heat-inactivated FCS, 100 U/mL penicillin, 100 µg/mL
streptomycin, and 2 mmol/L glutamine. Human monocytes were freshly
isolated from healthy donor blood by Ficoll-Hypaque
centrifugation and by an adherence method described
previously.26a The obtained monocytes were treated
with different agents for 5 minutes at 37°C in serum-free medium and
then were lysed for Western blot analysis.
Lipoprotein Isolation and Oxidation
LDLs (density=1.019 to 1.063 g/mL) were separated from freshly
drawn normal human plasma by sequential
ultracentrifugation as described
previously.26 The LDLs obtained were subjected to
oxidative modification by Cu2+ incubation (5
µmol/L CuSO4, 20 hours at 37°C).
Western Blot Analysis
THP-1 cells were cultured at a density of
106/mL. The growth medium was removed and
replaced with medium containing 0.1% serum for 24 hours. After being
treated with different agents at 37°C in serum-free medium, the cells
were lysed and then analyzed by SDS-PAGE, essentially as
described previously.26
Immunoprecipitation and p38 and p42/44 Kinase Assay
After being stimulated with OxLDL or LPC in serum-free medium,
the cells were lysed with lysis buffer. For p38 activity assay, cell
lysates were subjected to immunoprecipitation to detect p38
kinase activity using the p38 kinase assay kit according to the
manufacturers instructions.26 This protocol measures
p38-induced phosphorylation of recombinant ATF-2 fusion
protein, as assessed by Western blotting using phosphoATF-2 antibody.
p42/44 kinase activity was measured using myelin basic protein as a
substrate, as described previously.26b
Chemotaxis Assay
Chemotaxis was assessed using a transwell cell chemotactic
assay as described previously.26c During treatments and
chemotaxis assay, no significant cellular toxicity using various
agents, including SB203580, SKF86002, and PD98059 was observed, as
assessed by trypan blue exclusion and lactate dehydrogenase leakage
measurement.
Plasmids and Transient Transfection
Flag-tagged wild-type p38 and its dominant-negative mutant,
p38AF (TGY
AGF), cDNAs were in the pcDNA3 vector (Invitrogen) as
described17 and were purified with an EndoFree Plasmid
Maxi kit (Qiagen). THP-1 cells were transfected with p38
constructs by electroporation using the Gene Pulser II electroporation
system with radio frequency module (Bio-Rad) according to the
manufacturers instructions. Two days after transfection, cells were
subjected to chemotaxis assay, and cellular extracts were obtained for
Western blot analysis. The similar transfection efficiency
(
50%) was verified with fluorescent microscope and flow
cytometry by cotransfection with control green fluorescent
protein (GFP) cDNA.
cAMP Assay
Cells were challenged with OxLDL or LPC in the presence of
10 µmol/L forskolin and 500 µmol/L
3-isobutyl-1-methylxanthine at 37°C for 10 minutes. The cAMP level of
each sample was determined using radioimmunoassay as described
previously.26
Statistical Analysis
Results of the experiments are expressed as mean±SD. The
Student t test was used for statistical analysis of
the results. Values of P<0.05 were considered to be
significant.
An expanded Materials and Methods section is available online at http://www.circresaha.org.
| Results |
|---|
|
|
|---|
|
It has been established that p38 is activated by dual
phosphorylation of Thr180 and Tyr182 residues and that
p42/44 is activated by phosphorylation of
Thr202 and Tyr204 residues. Therefore, the
phosphorylation of MAPK has been widely used to
represent its activation. MAPK activity after OxLDL or LPC
stimulation was further measured in THP-1 cells. The results showed
that OxLDL and LPC significantly stimulated both p38 and p42/44
activity (Figure 1B
) using an in vitro kinase assay, which was
consistent with the results from the MAPK
phosphorylation assay. The activity of p38 was
effectively blocked by pretreatment of the cells with SB203580, a
specific inhibitor of p38 (Figure 1B
, top), whereas
the p42/44 phosphorylation and activation were
inhibited by PD98059, a selective inhibitor of MAPK/ERK
kinase 1 (MEK1), which was the upstream activator of p42/44
(data not shown), as shown previously.26d
In addition, in freshly isolated human peripheral blood
monocytes, OxLDL/LPC also efficiently induced
phosphorylation of p38 and p42/44 (Figure 1C
).
LPC Dose and Time Dependently Stimulated
Phosphorylation of p38 and p42/44
Phosphorylation of both p38 and p42/44 was
stimulated by LPC in a dose-dependent manner, with the maximal response
(6.9±0.7- and 7.3±0.8-fold versus control) at 25 µg/mL and the
half-maximal response at
2.5 µg/mL (Figure 2A
). The time course of the LPC effects
showed that a significant stimulation of p38 and p42/44
phosphorylation occurred rapidly, within 1 minute of
exposure to LPC, and that the maximal stimulation of MAPK was achieved
at 5 minutes (Figure 2B
). Then, phosphorylation
of both kinds of MAPK declined but remained at a detectable level by 60
minutes. Additionally, there appeared to be some difference in dose
curve and time course between phosphorylation of p38,
p42, and p44 as stimulated by LPC.
|
Inhibition of p38 but Not p42/44 Reduced OxLDL-/LPC-Induced
Chemotaxis
It has been reported that both OxLDL and LPC can induce chemotaxis
of monocytes4 10 and T lymphocytes.5 The
current study demonstrated that treatment of THP-1 cells with OxLDL (0
to 50 µg/mL) and LPC (0 to 25 µg/mL) also produced a significant
dose-dependent chemotaxis, whereas LDL or phosphatidylcholine (PC)
exerted no such effects (Figures 3A
and 3B
). The potential correlation between MAPK activation and chemotaxis
stimulated by OxLDL/LPC was further tested. Pretreatment of THP-1 cells
with the p38 inhibitors (SB203580 and SKF86002) greatly
inhibited OxLDL-/LPC-induced chemotaxis (Figure 3C
). In
contrast, pretreatment with PD98059 did not affect the
OxLDL-/LPC-induced chemotactic effects (Figure 3C
). Furthermore,
SB203580 dose dependently both inhibited OxLDL-/LPC-stimulated dual
phosphorylation of p38 (data not shown) and blocked p38
activity using an in vitro p38 kinase assay kit (Figure 4A
) with reported potency
(IC50) of 0.6 µmol/L. SB203580 also dose
dependently inhibited OxLDL-/LPC-induced chemotaxis (Figure 4B
)
at similar potency (IC50
1 µmol/L).
|
|
Expression of Dominant-Negative p38 (p38AF) Significantly
Attenuated OxLDL-/LPC-Stimulated Chemotaxis
To further confirm the effects of p38 in the chemotaxis, we
transfected wild-type p38 or its dominant-negative mutant p38AF
construct in THP-1 cells with electroporation. Transfection of both p38
constructs was verified by monitoring of cotransfected GFP (data not
shown) or by Western blot analysis using anti-flag monoclonal
antibody (Figure 5A
, left). The
transfected wild-type p38 could be activated by LPC stimulation
as detected by anti-phospho-p38 antibody, whereas the p38AF failed to
be activated by LPC (Figure 5A
, right). Consequently,
expression of wild-type p38 significantly increased
OxLDL-/LPC-stimulated chemotaxis of THP-1 cells, whereas expression of
p38AF markedly reduced directed chemotaxis of these cells (Figure 5B
). The fact that chemotaxis was not completely blocked by
p38AF might be due to the limitation of transfection efficiency.
|
p38 Activation by LPC Was Mediated by Pertussis Toxin
(PTX)Sensitive G Proteins
The possible signal transduction pathway mediating LPC activation
of p38 was further investigated. Pretreatment of THP-1 cells with
polyinosinic acid (poly I) or dextran sulfate (50 µg/mL, data not
shown), each of which is an LDL receptor/scavenger receptor
inhibitor, displayed no effect on the stimulation of p38
phosphorylation by LPC (Figure 6A
). In addition, with preincubation with
tyrphostin 51 or genistein (25 µmol/L, data not shown), the
tyrosine kinase inhibitors did not affect the LPC
stimulation of p38 phosphorylation (Figure 6A
).
However, p38 phosphorylation induced by LPC was
strongly inhibited when cells were preincubated with PTX (Figure 6A
), an effective blocker of Gi/Go proteins. As control,
pretreatment of cells with cholera toxin (CTX) hardly affected
LPC-induced phosphorylation of p38 (Figure 6A
).
OxLDL-induced phosphorylation of p38 was also subjected
to similar regulation (Figure 6B
). Moreover, LPC as well as
OxLDL could significantly inhibit forskolin-stimulated accumulation of
cAMP, which was also PTX sensitive (Figure 6C
). Taken together,
these data indicate that the effects of OxLDL/LPC were most likely
mediated by PTX-sensitive Gi/Go proteins but not through the LDL
receptors, scavenger receptors, or tyrosine kinase receptors.
|
Phospholipase C (PLC) and Phosphatidylinositol 3-Kinase (PI3K) Were
Involved in the LPC-Induced Effects
PLC has been shown to be an important component of the
signaling pathways in activation of p38.27 As
presented in Figure 7A
, U73122, a
PLC inhibitor that has been shown to specifically inhibit
phosphoinositide hydrolysis, considerably blocked p38
phosphorylation induced by LPC. As control, U73343, the
inactive structural analogue of U73122, failed to block the LPC-induced
p38 activation. Neither compound displayed any significant effect on
basal p38 phosphorylation. The data suggested that PLC
might be a signaling molecule involved in the LPC-induced p38
activation. In addition, as presented in Figure 7B
, treatment of cells with selective PI3K inhibitors
(wortmannin and LY294002) significantly reduced LPC-stimulated p38
phosphorylation, suggesting that PI3K might participate
in the p38 activation by LPC.
|
PTX-Sensitive G Proteins, PLC, and PI3K Were Also Included in the
OxLDL-/LPC-Induced Chemotaxis
Further experiments were performed to test whether these agents,
which were involved in OxLDL-/LPC-stimulated p38 activation, also exert
effects on OxLDL-/LPC-induced chemotaxis. The data showed that PTX,
U73122, and wortmannin effectively reduced OxLDL-/LPC-stimulated
chemotaxis of THP-1 cells (Figure 8A
),
indicating that the events of p38 activation and chemotaxis are
parallel with a causal correlation. Additionally, U73122, but not
wortmannin, exhibited a likely synergistic effect with reduced
concentration (1 µmol/L) of SB203580, suggesting that the PLC
pathway is in a parallel relationship, and the PI3K pathway is in a
sequential relationship, with p38 signaling.
|
| Discussion |
|---|
|
|
|---|
Scavenger receptors, a family of trimeric membrane
glycoproteins at the surface of monocytes, can specifically
mediate the uptake of OxLDL as well as LPC to exert their biological
activities. So far, several different scavenger receptors with a single
membrane-spanning domain for OxLDL uptake have been
identified,3 28 but none of these receptors is reported to
couple to any kind of heterotrimeric G proteins. Recently, OxLDL was
reported to induce a rapid and transient rise in
[Ca2+]i and suppress
activation of nuclear factor
B in
macrophages,29 which are both sensitive to PTX.
LPC has also been shown to stimulate PLC via PTX-sensitive G proteins
in HL-60 cells.30 Our data more clearly demonstrated that
acute activation of p38 by OxLDL/LPC was not mediated by these
scavenger receptors in THP-1 cells. Instead, OxLDL/LPC could
effectively stimulate PTX-sensitive G proteins, which in turn mediated
inhibition of cAMP accumulation. The finding that both p38 activation
and chemotaxis induced by OxLDL/LPC were blocked by PTX pretreatment of
cells further supports the mediation of the observed effects by
PTX-sensitive G proteins. It is not known yet whether OxLDL/LPC
directly activate G proteins via interaction with cell
membranes or whether they activate G proteins via the unknown G
proteincoupled receptors. Furthermore, whether p38 can be
activated directly or indirectly via uptake of OxLDL/LPC into
the cells through the scavenger receptors warrants further
investigation. Recent reports revealed that PI3K participates in
activation of p38,27 and PI3K is required for VSMC
migration.31 The present data further indicated that
PI3K and p38 were involved in chemotaxis. Additional intensive
investigation needs to be done to elucidate the relationship among
PI3K, PLC, and p38 in signaling, and their definite effects in cellular
chemotaxis or migration.
It has been established that p38 or p42/44 activation induces
different transcription factors to exert its distinctive biological
functions. p38 can be activated by several kinds of growth
factors and cytokines, which subsequently induces actin
reorganization and endothelial cell
migration,20 21 32 as well as neutrophil
chemotaxis.33 34 35 p38 is also critical for
endothelial expression of monocyte chemoattractant
protein-1,36 which is a potent chemokine for monocytes. In
the present study, p38 activation was shown to functionally
associate with and be critically involved in monocytic THP-1 cell
chemotaxis induced by OxLDL/LPC. In addition, because of p38
isoforminhibitory selectivity of SB203580 (inhibiting
p38
and -ß, but not -
or -
),37 the effects of
LPC may act via activation of the first 2 isoforms. In the present
study, LPC was able to activate transfected exogenous p38
(p38
). A recent report indicates that p38ß cannot be detected in
monocytes and macrophages.38 Our preliminary data
also demonstrated that LPC failed to activate transfected
exogenous p38ß (data not shown). All of these findings indicated that
only p38
might be responsible for the LPC-induced monocytic
chemotaxis. Also, it is not clear whether JNK/SAPK, which can be
activated by LPC,25 39 is involved in the
LPC-directed chemotaxis, and this warrants further investigation.
In the current study, our data showed for the first time that in monocytic cells, OxLDL, which has been demonstrated to be critically involved in atherogenesis, could strongly stimulate phosphorylation and activation of both p38 and p42/44. Our results also demonstrated that the phospholipid LPC, among several moieties of OxLDL, was the major active component responsible for these activities of OxLDL. More interestingly, although OxLDL and LPC were able to efficiently activate both kinds of MAPK, only inhibition of p38, not of p42/44, markedly reduced OxLDL-/LPC-induced chemotaxis in THP-1 cells. Our results also revealed that the effects of OxLDL/LPC were apparently not mediated by the classical scavenger receptors for OxLDL or by the general tyrosine kinase receptors, but were likely mediated by PTX-sensitive G proteins and somehow involved PLC and PI3K. Thus, this study not only demonstrated activation of p38 and p42/44 by OxLDL/LPC but also established the functional importance of OxLDL/LPC activation of p38 in the OxLDL-/LPC-induced chemotaxis in monocytic THP-1 cells. All of the evidence, taken together, implies that p38 may play an active role in atherogenesis and that selective inhibition of p38 in monocytes may help to prevent the initiation and progression of atherosclerosis.
| Acknowledgments |
|---|
Received February 2, 2000; accepted May 15, 2000.
| References |
|---|
|
|
|---|
2.
Berliner JA, Navab M, Fogelman AM, Frank JS,
Demer LL, Edwards PA, Watson AD, Lusis AJ.
Atherosclerosis: basic mechanisms. Oxidation,
inflammation, and genetics. Circulation. 1995;91:24882496.
3.
Steinberg D. Lewis A. Conner Memorial Lecture:
oxidative modification of LDL and atherogenesis.
Circulation. 1997;95:10621071.
4.
Quinn MT, Parthasarathy S, Fong LG, Steinberg D.
Oxidatively modified low density lipoproteins: a potential role in
recruitment and retention of monocyte/macrophages during
atherogenesis. Proc Natl Acad Sci U S A. 1987;84:29952998.
5. McMurray HF, Parthasarathy S, Steinberg D. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest. 1993;92:10041008.
6. Kume N, Cybulsky MI, Gimbrone MA Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest. 1992;90:11381144.
7.
Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima
S, Yokoyama M. Low concentration of oxidized low-density lipoprotein
and lysophosphatidylcholine upregulate constitutive nitric oxide
synthase mRNA expression in bovine aortic endothelial
cells. Circ Res. 1995;76:958962.
8.
Nakano T, Raines EW, Abraham JA, Klagsbrun M,
Ross R. Lysophosphatidylcholine upregulates the level of
heparin-binding epidermal growth factor-like growth factor mRNA in
human monocytes. Proc Natl Acad Sci U S A. 1994;91:10691073.
9. Kume N, Gimbrone MA Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest. 1994;93:907911.
10.
Quinn MT, Parthasarathy S, Steinberg D.
Lysophosphatidylcholine: a chemotactic factor for human monocytes and
its potential role in atherogenesis. Proc Natl Acad Sci
U S A. 1988;85:28052809.
11.
Kohno M, Yokokawa K, Yasunari K, Minami M, Kano
H, Hanehira T, Yoshikawa J. Induction by lysophosphatidylcholine,
a major phospholipid component of atherogenic lipoproteins, of human
coronary artery smooth muscle cell migration.
Circulation. 1998;98:353359.
12.
Force T, Pombo CM, Avruch JA, Bonventre JV,
Kyriakis JM. Stress-activated protein kinases in
cardiovascular disease. Circ Res. 1996;78:947953.
13. New L, Han J. The p38 MAP kinase pathway and its biological function. Trends Cardiovasc Med. 1998;8:220229.[Medline] [Order article via Infotrieve]
14.
Sugden PH, Clerk A. "Stress-responsive"
mitogen-activated protein kinases (c-Jun N-terminal kinases and
p38 mitogen-activated protein kinases) in the
myocardium. Circ Res. 1998;83:345352.
15.
Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase
targeted by endotoxin and hyperosmolarity in mammalian cells.
Science. 1994;265:808811.
16. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372:739746.[Medline] [Order article via Infotrieve]
17.
Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S,
Han J. Characterization of the structure and function of a new
mitogen-activated protein kinase (p38ß). J
Biol Chem. 1996;271:1792017926.
18.
Li Z, Jiang Y, Ulevitch RJ, Han J. The primary
structure of p38
: a new member of p38 group of MAP kinases.
Biochem Biophys Res Commun. 1996;228:334340.[Medline]
[Order article via Infotrieve]
19.
Jiang Y, Gram H, Zhao M, New L, Gu J, Feng L, Di
Padova F, Ulevitch RJ, Han J. Characterization of the structure
and function of the fourth member of p38 group
mitogen-activated protein kinases, p38
. J
Biol Chem. 1997;272:3012230128.
20. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 1997;15:21692177.[Medline] [Order article via Infotrieve]
21.
Hedges JC, Dechert MA, Yamboliev IA, Martin JL,
Hickey E, Weber LA, Gerthoffer WT. A role for p38(MAPK)/HSP27 pathway
in smooth muscle cell migration. J Biol Chem. 1999;274:2421124219.
22.
Kusuhara M, Chait A, Cader A, Berk BC. Oxidized
LDL stimulates mitogen-activated protein kinases in smooth
muscle cells and macrophages. Arterioscler Thromb Vasc
Biol. 1997;17:141148.
23. Deigner HP, Claus R. Stimulation of mitogen activated protein kinase by LDL and oxLDL in human U-937 macrophage-like cells. FEBS Lett. 1996;385:149153.[Medline] [Order article via Infotrieve]
24.
Yamakawa T, Eguchi S, Yamakawa Y, Motley ED,
Numaguchi K, Utsunomiya H, Inagami T. Lysophosphatidylcholine
stimulates MAP kinase activity in rat vascular smooth muscle cells.
Hypertension. 1998;31:248253.
25. Ozaki H, Ishii K, Arai H, Kume N, Kita T. Lysophosphatidylcholine activates mitogen-activated protein kinases by a tyrosine kinase-dependent pathway in bovine aortic endothelial cells. Atherosclerosis. 1999;143:261266.[Medline] [Order article via Infotrieve]
26.
Jing Q, Xin SM, Cheng ZJ, Zhang WB, Zhang R, Qin
YW, Pei G. Activation of p38 mitogen-activated protein kinase
by oxidized LDL in vascular smooth muscle cells: mediation via
pertussis toxin-sensitive G proteins and association with oxidized
LDL-induced cytotoxicity. Circ Res. 1999;84:831839.
26. Manthey CL, Wang SW, Kinney SD, Yao Z. SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes. J Leukoc Biol.. 1998;64:409417.[Abstract]
26. Lou LG, Zhang Z, Ma L, Pei G. Nociceptin/orphanin FQ activates mitogen-activated protein kinase in Chinese hamster ovary cells expressing opioid receptor-like receptor. J Neurochem.. 1998;70:13161322.[Medline] [Order article via Infotrieve]
26.
Zhao J, Ben LH, Wu YL, Hu W, Ling K, Xin SM, Nie
HL, Ma L, Pei G. Anti-HIV agent trichosanthin enhances the capabilities
of chemokines to stimulate chemotaxis and G protein activation, and
this is mediated through interaction of trichosanthin and chemokine
receptors. J Exp Med.. 1999;190:101111.
26.
Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel
AR. PD 098059 is a specific inhibitor of the activation of
mitogen-activated protein kinase kinase in vitro and in vivo. J
Biol Chem.. 1995;270:2748927494.
27. Rane MJ, Carrithers SL, Arthur JM, Klein JB, McLeish KR. Formyl peptide receptors are coupled to multiple mitogen-activated protein kinase cascades by distinct signal transduction pathways: role in activation of reduced nicotinamide adenine dinucleotide oxidase. J Immunol. 1997;159:50705078.[Abstract]
28. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:7377.[Medline] [Order article via Infotrieve]
29.
Schackelford RE, Misra UK, Florine Casteel K,
Thai SF, Pizzo SV, Adams DO. Oxidized low density lipoprotein
suppresses activation of NF
B in macrophages via a
pertussis toxin-sensitive signaling mechanism. J Biol
Chem. 1995;270:34753478.
30. Okajima F, Sato K, Tomura H, Kuwabara A, Nochi H, Tamoto K, Kondo Y, Tokumitsu Y, Ui M. Stimulatory and inhibitory actions of lysophosphatidylcholine, depending on its fatty acid residue, on the phospholipase C/Ca2+ system in HL-60 leukaemia cells. Biochem J. 1998;336:491500.
31.
Duan C, Bauchat JR, Hsieh T. Phosphatidylinositol
3-kinase is required for insulin-like growth factor I-induced vascular
smooth muscle cell proliferation and migration. Circ Res. 2000;86:1523.
32.
Matsumoto T, Yokote K, Tamura K, Takemoto M, Ueno
H, Saito Y, Mori S. Platelet-derived growth factor
activates p38 mitogen-activated protein kinase through
a Ras-dependent pathway that is important for actin reorganization and
cell migration. J Biol Chem. 1999;274:1395413960.
33. Hannigan M, Zhan L, Ai Y, Huang CK. The role of p38 MAP kinase in TGF-ß1-induced signal transduction in human neutrophils. Biochem Biophys Res Commun. 1998;246:5558.[Medline] [Order article via Infotrieve]
34.
Zu YL, Qi J, Gilchrist A, Fernandez GA, Vazquez
Abad D, Kreutzer DL, Huang CK, Shaafi RI. p38
mitogen-activated protein kinase activation is required for
human neutrophil function triggered by TNF-
or FMLP
stimulation. J Immunol. 1998;160:19821989.
35. Nick JA, Avdi NJ, Young SK, Knall C, Gerwins P, Johnson GL, Worthen GS. Common and distinct intracellular signaling pathways in human neutrophils utilized by platelet activating factor and FMLP. J Clin Invest. 1997;99:975986.[Medline] [Order article via Infotrieve]
36.
Goebeler M, Kilian K, Gillitzer R, Kunz M,
Yoshimura T, Brocker EB, Rapp UR, Ludwig S. The MKK6/p38 stress kinase
cascade is critical for tumor necrosis factor-
-induced
expression of monocyte-chemoattractant protein-1 in
endothelial cells. Blood. 1999;93:857865.
37. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, Young PR. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun. 1997;235:533538.[Medline] [Order article via Infotrieve]
38.
Hale KK, Trollinger D, Rihanek M, Manthey CL.
Differential expression and activation of p38 mitogen-activated
protein kinase
, ß,
, and
in inflammatory cell
lineages. J Immunol. 1999;162:42464252.
39.
Fang X, Gibson S, Flowers M, Furui T, Bast RC Jr,
Mills GB. Lysophosphatidylcholine stimulates activator
protein 1 and the c-Jun N-terminal kinase activity. J Biol
Chem. 1997;272:1368313689.
This article has been cited by other articles:
![]() |
M. Tan, F. Hao, X. Xu, G. M. Chisolm, and M.-Z. Cui Lysophosphatidylcholine Activates a Novel PKD2-Mediated Signaling Pathway That Controls Monocyte Migration Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1376 - 1382. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Ojala, T. E. Hirvonen, M. Hermansson, P. Somerharju, and J. Parkkinen Acyl chain-dependent effect of lysophosphatidylcholine on human neutrophils J. Leukoc. Biol., December 1, 2007; 82(6): 1501 - 1509. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Frasch, K. Zemski-Berry, R. C. Murphy, N. Borregaard, P. M. Henson, and D. L. Bratton Lysophospholipids of Different Classes Mobilize Neutrophil Secretory Vesicles and Induce Redundant Signaling through G2A J. Immunol., May 15, 2007; 178(10): 6540 - 6548. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhu, J. Learoyd, S. Butt, L. Zhu, P. V. Usatyuk, V. Natarajan, N. M. Munoz, and A. R. Leff Regulation of Eosinophil Adhesion by Lysophosphatidylcholine via a Non-Store-Operated Ca2+ Channel Am. J. Respir. Cell Mol. Biol., May 1, 2007; 36(5): 585 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Faustino, L. N. W. Stronger, M. N. Richard, M. P. Czubryt, D. A. Ford, M. A. Prociuk, E. Dibrov, and G. N. Pierce RanGAP-Mediated Nuclear Protein Import in Vascular Smooth Muscle Cells Is Augmented by Lysophosphatidylcholine Mol. Pharmacol., February 1, 2007; 71(2): 438 - 445. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Conway and M. Kinter Dual Role of Peroxiredoxin I in Macrophage-derived Foam Cells J. Biol. Chem., September 22, 2006; 281(38): 27991 - 28001. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Li, H. Tanaka, H. H. Wang, S. Yoshiyama, H. Kumagai, A. Nakamura, D. L. Brown, S. E. Thatcher, G. L. Wright, and K. Kohama Intracellular signal transduction for migration and actin remodeling in vascular smooth muscle cells after sphingosylphosphorylcholine stimulation Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1262 - H1272. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Poeckel, L. Tausch, S. George, J. Jauch, and O. Werz 3-O-Acetyl-11-keto-boswellic Acid Decreases Basal Intracellular Ca2+ Levels and Inhibits Agonist-Induced Ca2+ Mobilization and Mitogen-Activated Protein Kinase Activation in Human Monocytic Cells J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 224 - 232. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Maghazachi Insights into Seven and Single Transmembrane-Spanning Domain Receptors and Their Signaling Pathways in Human Natural Killer Cells Pharmacol. Rev., September 1, 2005; 57(3): 339 - 357. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Simoes and I. M. Fierro Involvement of the Rho-Kinase/Myosin Light Chain Kinase Pathway on Human Monocyte Chemotaxis Induced by ATL-1, an Aspirin-Triggered Lipoxin A4 Synthetic Analog J. Immunol., August 1, 2005; 175(3): 1843 - 1850. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Schecter, A. B. Berman, L. Yi, H. Ma, C. M. Daly, K. Soejima, B. J. Rollins, I. F. Charo, and M. B. Taubman MCP-1-dependent signaling in CCR2-/- aortic smooth muscle cells J. Leukoc. Biol., June 1, 2004; 75(6): 1079 - 1085. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Dobreva, G. Waeber, V. Mooser, R. W. James, and C. Widmann LDLs induce fibroblast spreading independently of the LDL receptor via activation of the p38 MAPK pathway J. Lipid Res., December 1, 2003; 44(12): 2382 - 2390. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Scholz, A. Yndestad, J. K. Damas, T. Waehre, S. Tonstad, P. Aukrust, and B. Halvorsen 8-Isoprostane increases expression of interleukin-8 in human macrophages through activation of mitogen-activated protein kinases Cardiovasc Res, October 1, 2003; 59(4): 945 - 954. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lin and R. D. Ye The Lysophospholipid Receptor G2A Activates a Specific Combination of G Proteins and Promotes Apoptosis J. Biol. Chem., April 11, 2003; 278(16): 14379 - 14386. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Drobnik, G. Liebisch, F.-X. Audebert, D. Frohlich, T. Gluck, P. Vogel, G. Rothe, and G. Schmitz Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients J. Lipid Res., April 1, 2003; 44(4): 754 - 761. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sun, Z. Cheng, L. Ma, and G. Pei beta -Arrestin2 Is Critically Involved in CXCR4-mediated Chemotaxis, and This Is Mediated by Its Enhancement of p38 MAPK Activation J. Biol. Chem., December 13, 2002; 277(51): 49212 - 49219. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Koul, M. Menon, L. S. Chaturvedi, S. Koul, A. Sekhon, A. Bhandari, and M. Huang COM Crystals Activate the p38 Mitogen-activated Protein Kinase Signal Transduction Pathway in Renal Epithelial Cells J. Biol. Chem., September 20, 2002; 277(39): 36845 - 36852. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Burysek, T. Syrovets, and T. Simmet The Serine Protease Plasmin Triggers Expression of MCP-1 and CD40 in Human Primary Monocytes via Activation of p38 MAPK and Janus Kinase (JAK)/STAT Signaling Pathways J. Biol. Chem., August 30, 2002; 277(36): 33509 - 33517. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Wang, Y. L. Siow, and K. O Homocysteine induces monocyte chemoattractant protein-1 expression by activating NF-{kappa}B in THP-1 macrophages Am J Physiol Heart Circ Physiol, June 1, 2001; 280(6): H2840 - H2847. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Bruyninckx, K. M. Comerford, D. W. Lawrence, and S. P. Colgan Phosphoinositide 3-kinase modulation of {beta}3-integrin represents an endogenous "braking" mechanism during neutrophil transmatrix migration Blood, May 15, 2001; 97(10): 3251 - 3258. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ashida, H. Arai, M. Yamasaki, and T. Kita Distinct Signaling Pathways for MCP-1-dependent Integrin Activation and Chemotaxis J. Biol. Chem., May 4, 2001; 276(19): 16555 - 16560. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |